Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trial | Synapse
March 3, 2026
Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trial
Key Points
Antituberculosis therapy significantly improved outcomes in HIV-related sepsis cases, compared to standard care.
A total of 200 patients were involved across Tanzania and Uganda, showing marked health benefits.
Randomised controlled trial design confirms the effectiveness of immediate versus high-dose interventions.
The findings suggest that altering treatment approaches can lead to better health outcomes for affected individuals.